Allogene Therapeutics, Inc. (ALLO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue - related party | - | - | - | - |
| Research and development | 40,156 | 50,200 | 44,713 | 50,355 |
| Impairment of long-lived assets | 2,382 | - | 10,728 | 4,989 |
| General and administrative | 14,281 | 14,991 | 16,333 | 16,087 |
| Total operating expenses | 56,819 | 65,191 | 71,774 | 71,431 |
| Loss from operations | -56,819 | -65,191 | -71,774 | -71,431 |
| Interest and other income, net | - | - | - | 4,988 |
| Other income (expenses), net | -43 | 92 | -1,124 | 85 |
| Interest expense | 268 | 150 | 100 | - |
| Interest and other income, net | 6,187 | 5,516 | 6,705 | - |
| Total other income (expense), net | 5,876 | 5,458 | 5,481 | 5,073 |
| Net loss | -50,943 | -59,733 | -66,293 | -66,358 |
| Net unrealized gain (loss) on available-for-sale investments | -88 | 132 | 937 | 147 |
| Net comprehensive loss | -51,031 | -59,601 | -65,356 | -66,211 |
| Net loss per share, basic (in dollars per share) | -0.23 | -0.28 | -0.32 | -0.35 |
| Net loss per share, diluted (in dollars per share) | -0.23 | -0.28 | -0.32 | -0.35 |
| Weighted-average number of shares used in computing net loss per share, basic (in shares) | 218,929,548 | 215,358,619 | 209,188,551 | 190,026,638 |
| Weighted-average number of shares used in computing net loss per share, diluted (in shares) | 218,929,548 | 215,358,619 | 209,188,551 | 190,026,638 |